WGU D116 Advanced Pharmacology OA
Exam Actual Exam 2026/2027 with
Detailed Rationales | Complete
Exam-Style Questions | Pass Guaranteed
– A+ Graded
TABLE OF CONTENTS
Section 1: Pharmacokinetics & Pharmacodynamics (Questions 1-8)
Section 2: Autonomic Nervous System Pharmacology (Questions 9-17)
Section 3: Cardiovascular Pharmacology (Questions 18-27)
Section 4: Respiratory Pharmacology (Questions 28-34)
Section 5: Central Nervous System Pharmacology (Questions 35-44)
Section 6: Endocrine Pharmacology (Questions 45-53)
Section 7: Antimicrobial & Antiviral Agents (Questions 54-63)
Section 8: Chemotherapy & Immunomodulators (Questions 64-69)
Section 9: Pain Management & Analgesics (Questions 70-77)
Section 10: Gastrointestinal & Renal Pharmacology (Questions 78-84)
Section 11: Drug Interactions & Adverse Effects (Questions 85-92)
Section 12: Special Populations (Questions 93-100)
SECTION 1: Pharmacokinetics & Pharmacodynamics
(Questions 1-8)
,Q1: A patient with chronic kidney disease (CKD) stage 4 is prescribed a medication that is
primarily eliminated by renal excretion. Which pharmacokinetic parameter is most likely to
be significantly altered in this patient?
A. Increased volume of distribution
B. Decreased clearance and prolonged half-life
C. Increased first-pass metabolism
D. Enhanced protein binding
Correct Answer: B
Rationale: In patients with CKD stage 4 (GFR 15-29 mL/min), renal clearance of drugs is
significantly reduced, leading to decreased elimination and prolonged half-life. This
requires dose adjustment to prevent drug accumulation and toxicity. Volume of distribution
may change but is less predictable, first-pass metabolism is hepatic, and protein binding
may be altered but doesn't directly affect elimination as significantly as reduced GFR.
Advanced practice nurses must calculate appropriate dose reductions based on creatinine
clearance for renally eliminated drugs.
Q2: A patient is taking warfarin (S-warfarin) and phenytoin concurrently. Phenytoin induces
CYP2C9 enzymes. What is the expected pharmacokinetic interaction and clinical
consequence?
A. Increased warfarin levels leading to bleeding risk
B. Decreased warfarin levels leading to reduced anticoagulation effect
C. No significant interaction between these medications
D. Increased protein binding of warfarin
Correct Answer: B
Rationale: Phenytoin is a potent inducer of CYP2C9, the primary enzyme responsible for
metabolizing S-warfarin (the more potent isomer). Enzyme induction increases warfarin
metabolism, decreasing plasma concentrations and reducing anticoagulation effect,
potentially leading to therapeutic failure and thrombosis risk. This is a classic
,pharmacokinetic interaction requiring INR monitoring and potential warfarin dose increase.
Advanced practice providers must anticipate enzyme induction effects when adding or
removing inducing agents.
Q3: Which statement best describes the concept of "steady-state concentration" in
pharmacokinetics?
A. The concentration achieved after a single loading dose
B. The point where drug absorption equals drug elimination
C. The maximum concentration achieved after administration
D. The concentration at which toxic effects begin
Correct Answer: B
Rationale: Steady-state concentration occurs when the rate of drug administration equals
the rate of drug elimination, typically reached after 4-5 half-lives of continuous dosing. At
this point, plasma concentrations remain relatively constant if dosing continues at the same
rate and interval. This concept is crucial for determining when to measure therapeutic drug
levels and assess efficacy. Loading doses can achieve therapeutic levels faster but don't
represent steady-state, which requires maintenance dosing over time.
Q4: A patient with heart failure is prescribed digoxin. Which pharmacodynamic change is
most likely to occur in this patient compared to a healthy individual?
A. Increased sensitivity to digoxin's effects
B. Decreased sensitivity requiring higher doses
C. No change in pharmacodynamic response
D. Complete resistance to digoxin
Correct Answer: A
Rationale: Patients with heart failure often have increased sensitivity to digoxin's effects
due to altered electrolyte balance (particularly hypokalemia), impaired renal function, and
changes in receptor sensitivity. This increased sensitivity raises the risk of digoxin toxicity
, even at therapeutic serum concentrations. Advanced practice nurses must monitor for
signs of toxicity more closely in heart failure patients and consider lower initial doses. The
therapeutic window for digoxin is narrow, making this pharmacodynamic alteration clinically
significant.
Q5: Which medication characteristic would most likely result in a high volume of distribution
(Vd)?
A. Highly water-soluble with low protein binding
B. Highly lipophilic with extensive tissue binding
C. Large molecular weight with high polarity
D. Poor membrane permeability
Correct Answer: B
Rationale: Lipophilic drugs with extensive tissue binding distribute widely into fatty tissues
and intracellular spaces, resulting in a high volume of distribution. This means the drug is
extensively distributed beyond the plasma compartment. Drugs with high Vd are not easily
removed by dialysis and may require loading doses to achieve therapeutic concentrations.
Understanding Vd helps predict drug distribution patterns and dosing requirements,
especially in cases of overdose or toxicity.
Q6: A patient is taking a drug with zero-order elimination kinetics. Which statement
accurately describes this elimination pattern?
A. A constant fraction of the drug is eliminated per unit time
B. A constant amount of drug is eliminated per unit time regardless of concentration
C. Elimination rate increases as drug concentration increases
D. Elimination follows first-order kinetics at low concentrations
Correct Answer: B
Rationale: Zero-order elimination (saturation kinetics) occurs when elimination pathways
are saturated, resulting in a constant amount of drug eliminated per unit time regardless of
Exam Actual Exam 2026/2027 with
Detailed Rationales | Complete
Exam-Style Questions | Pass Guaranteed
– A+ Graded
TABLE OF CONTENTS
Section 1: Pharmacokinetics & Pharmacodynamics (Questions 1-8)
Section 2: Autonomic Nervous System Pharmacology (Questions 9-17)
Section 3: Cardiovascular Pharmacology (Questions 18-27)
Section 4: Respiratory Pharmacology (Questions 28-34)
Section 5: Central Nervous System Pharmacology (Questions 35-44)
Section 6: Endocrine Pharmacology (Questions 45-53)
Section 7: Antimicrobial & Antiviral Agents (Questions 54-63)
Section 8: Chemotherapy & Immunomodulators (Questions 64-69)
Section 9: Pain Management & Analgesics (Questions 70-77)
Section 10: Gastrointestinal & Renal Pharmacology (Questions 78-84)
Section 11: Drug Interactions & Adverse Effects (Questions 85-92)
Section 12: Special Populations (Questions 93-100)
SECTION 1: Pharmacokinetics & Pharmacodynamics
(Questions 1-8)
,Q1: A patient with chronic kidney disease (CKD) stage 4 is prescribed a medication that is
primarily eliminated by renal excretion. Which pharmacokinetic parameter is most likely to
be significantly altered in this patient?
A. Increased volume of distribution
B. Decreased clearance and prolonged half-life
C. Increased first-pass metabolism
D. Enhanced protein binding
Correct Answer: B
Rationale: In patients with CKD stage 4 (GFR 15-29 mL/min), renal clearance of drugs is
significantly reduced, leading to decreased elimination and prolonged half-life. This
requires dose adjustment to prevent drug accumulation and toxicity. Volume of distribution
may change but is less predictable, first-pass metabolism is hepatic, and protein binding
may be altered but doesn't directly affect elimination as significantly as reduced GFR.
Advanced practice nurses must calculate appropriate dose reductions based on creatinine
clearance for renally eliminated drugs.
Q2: A patient is taking warfarin (S-warfarin) and phenytoin concurrently. Phenytoin induces
CYP2C9 enzymes. What is the expected pharmacokinetic interaction and clinical
consequence?
A. Increased warfarin levels leading to bleeding risk
B. Decreased warfarin levels leading to reduced anticoagulation effect
C. No significant interaction between these medications
D. Increased protein binding of warfarin
Correct Answer: B
Rationale: Phenytoin is a potent inducer of CYP2C9, the primary enzyme responsible for
metabolizing S-warfarin (the more potent isomer). Enzyme induction increases warfarin
metabolism, decreasing plasma concentrations and reducing anticoagulation effect,
potentially leading to therapeutic failure and thrombosis risk. This is a classic
,pharmacokinetic interaction requiring INR monitoring and potential warfarin dose increase.
Advanced practice providers must anticipate enzyme induction effects when adding or
removing inducing agents.
Q3: Which statement best describes the concept of "steady-state concentration" in
pharmacokinetics?
A. The concentration achieved after a single loading dose
B. The point where drug absorption equals drug elimination
C. The maximum concentration achieved after administration
D. The concentration at which toxic effects begin
Correct Answer: B
Rationale: Steady-state concentration occurs when the rate of drug administration equals
the rate of drug elimination, typically reached after 4-5 half-lives of continuous dosing. At
this point, plasma concentrations remain relatively constant if dosing continues at the same
rate and interval. This concept is crucial for determining when to measure therapeutic drug
levels and assess efficacy. Loading doses can achieve therapeutic levels faster but don't
represent steady-state, which requires maintenance dosing over time.
Q4: A patient with heart failure is prescribed digoxin. Which pharmacodynamic change is
most likely to occur in this patient compared to a healthy individual?
A. Increased sensitivity to digoxin's effects
B. Decreased sensitivity requiring higher doses
C. No change in pharmacodynamic response
D. Complete resistance to digoxin
Correct Answer: A
Rationale: Patients with heart failure often have increased sensitivity to digoxin's effects
due to altered electrolyte balance (particularly hypokalemia), impaired renal function, and
changes in receptor sensitivity. This increased sensitivity raises the risk of digoxin toxicity
, even at therapeutic serum concentrations. Advanced practice nurses must monitor for
signs of toxicity more closely in heart failure patients and consider lower initial doses. The
therapeutic window for digoxin is narrow, making this pharmacodynamic alteration clinically
significant.
Q5: Which medication characteristic would most likely result in a high volume of distribution
(Vd)?
A. Highly water-soluble with low protein binding
B. Highly lipophilic with extensive tissue binding
C. Large molecular weight with high polarity
D. Poor membrane permeability
Correct Answer: B
Rationale: Lipophilic drugs with extensive tissue binding distribute widely into fatty tissues
and intracellular spaces, resulting in a high volume of distribution. This means the drug is
extensively distributed beyond the plasma compartment. Drugs with high Vd are not easily
removed by dialysis and may require loading doses to achieve therapeutic concentrations.
Understanding Vd helps predict drug distribution patterns and dosing requirements,
especially in cases of overdose or toxicity.
Q6: A patient is taking a drug with zero-order elimination kinetics. Which statement
accurately describes this elimination pattern?
A. A constant fraction of the drug is eliminated per unit time
B. A constant amount of drug is eliminated per unit time regardless of concentration
C. Elimination rate increases as drug concentration increases
D. Elimination follows first-order kinetics at low concentrations
Correct Answer: B
Rationale: Zero-order elimination (saturation kinetics) occurs when elimination pathways
are saturated, resulting in a constant amount of drug eliminated per unit time regardless of
